Topics-in-Focus program

The EHA Guidelines Workshop, a meaningful and successful first Series!

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.

New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect

On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro diagnostic medical devices.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).